Follow the Biosimilars Forum on LinkedIn to stay up to date on the latest #biosimilars news and events – including Drug Information Association (DIA)'s Evolution of Biosimilars Development Workshop. Follow us here: linkedin.com/company/biosim…

Over the last decade, #biosimilars have saved $56 billion compared to what spending would have been without them. Yet, high out-of-pocket costs still force some patients to delay or skip treatment. Policymakers must act to ensure biosimilars remain accessible and affordable.

Only one month until Drug Information Association (DIA)'s Evolution of Biosimilars Development Workshop. Register now to join hundreds of industry leaders in the discussion on developing future biosimilars: bit.ly/4gWva5N

Next week, the Biosimilars Forum’s Chair of the Scientific Affairs Committee, Hillel Cohen, will discuss the development of future biosimilars. Learn more about Festival of Biologics #festivalofbiologics: bit.ly/4bDMifA

FDA-approved #biosimilars meet the highest safety and quality standards, ensuring they are safe and effective. Patients and providers can trust that biosimilars undergo rigorous evaluation before approval. Learn more: fda.gov/drugs/biosimil…

Executive Director of the Biosimilars Forum, Julie Reed, is proud to present a state of the industry at Drug Information Association (DIA)'s Evolution of Biosimilars Development Workshop. Register now to gain access to dozens of in-person workshops and presentations: bit.ly/4gWva5N

#Biosimilars are transforming healthcare by offering treatments that are, on average, 50% lower cost than the biologics they reference. Over the past decade, they’ve saved $56 billion and provided nearly 700 million days of therapy.

The development of more FDA-approved biosimilars could save patients $181 billion over the next five years! Learn more about these life-saving medicines here: biosimilarsforum.org #festivalofbiologics

#Biosimilars offer significant savings: $5.2B for U.S. taxpayers and $3.3B in out-of-pocket savings for #Medicare seniors. The Biosimilars Forum is working to make these savings a reality by increasing access and affordability.

The Biosimilars Forum supports Chair of the Scientific Affairs Committee, Hillel Cohen, as he discusses the development of biosimilars today at the Festival of Biologics.

Thank you, Festival of Biologics, for hosting the Biosimilars Forum! Now is the time to streamline biosimilar development and ensure patients have access to lower-cost treatments. Learn more about #biosimilars: biosimilarsforum.org/biosimilars-10… #festivalofbiologics

The Biosimilars Forum looks forward to the Drug Information Association (DIA) Evolution of Biosimilars Development Workshop this May. The Forum's Executive Director, Julie Reed, will deliver a state of the industry speech, with support from Forum members. Learn more: bit.ly/4gWva5N

Chronic diseases account for 90% of U.S. healthcare spending. Increased adoption of #biosimilars can provide quality care at a fraction of the cost. We will continue to urge Congress and the administration to dismantle the PBM monopoly that pushes high-rebate drugs for profit.

The DIA Evolution of Biosimilars Development Workshop is almost here! Next week, the Biosimilars Forum’s Executive Director, Julie Reed will address the state of the #biosimilars industry and the importance of streamlined development. Learn more: diaglobal.org/en/conference-…

Join the Biosimilars Forum and its members at the DIA Evolution of Biosimilars Development Workshop. Learn more about the conference here: diaglobal.org/en/conference-…

Developing more biosimilars means patients have increased access to lower-cost treatments. Learn more about the state of the #biosimilars industry at the DIA Evolution of Biosimilars Development Workshop: bit.ly/4gWva5N

Tomorrow, join Biosimilars Forum Executive Director Julie Reed as she highlights the growth of the #biosimilars industry during the Drug Information Association (DIA) Evolution of Biosimilars Development Workshop. Learn more about the workshop here: bit.ly/4gWva5N

#Biosimilars have improved the healthcare industry, providing patients with access to effective, lower-cost medicines. We thank you and all those who attended the DIA Evolution of Biosimilars Development Workshop for supporting our industry. biosimilarsforum.org

As Congress looks for ways to lower the cost of healthcare, we must continue to develop the answer, more biosimilars. Visit the Biosimilars Forum’s website to learn more about the opportunities patients have to access lower-cost treatments. biosimilarsforum.org/news/

Thank you to Drug Information Association (DIA) for hosting the Evolution of Biosimilars Development Workshop. We're proud to continue advancing the industry, ensuring patients always have access to lower-cost treatments. Learn more about #biosimilars here: bit.ly/41Abbo7